Objective To explore the application of bullfrog as the experimental object in pharmacoki-netic experiment drug dose-effect curve drawing and competitive antagonist pA2 determination.Methods The rectus abdominis muscle of bullfrog served as the sample.The semi-logarithmic molal concentration accumula-tion method was used.The effect of competitive antagonist-tubocurarine on the contraction action of acetyl-choline(ACh)agonist was observed.Results The rectus abdominis of bullfrog(regardless of gender)weighed 200-250 g served as the sample.The ACh solution of 1.3 × 10-4-1.3 × 10-1 mol/L series concen-trations could cause the contraction reaction of most specimens when adding the second and third doses,more-over which could make the contraction of the sample to reach the maximum effect;0.4X 10-3 mol/L tubocura-rine solution could effectively antagonize the effect of Ach;in addition,the contraction effect generated the specimen was highly correlated with the effect of bullfrog or toad as the experiment animal.Conclusion The determination conditions of bullfrog antagonistic parameters could meet the experimental requirements.

ObjectiveTo evaluate the efficacy and clinical safety of sodium glycididazole (CMNa)in thoracic esophageal squamous carcinoma.Methods From June 1,2008 to October 13,2009,66pathologically proved thoracic esophageal squamous carcinoma (stage Ⅱa-Ⅲ,stage Ⅳ with metastases only in supraclavicular lymph nodes,by AJCC 6th ed) were randomized into radiotherapy plus CMNa (A) or radiotherapy plus placebo (B) group.Radiotherapy was given by conventional schedule:1.8-2.0 Gy per fraction,5 times per week to a total dose of 66 Gy/6.6-7.2w.CMNa was given intravenously 800 mg/m2 3 times a week in solution of 100 ml saline within 30 minutes.Radiotherapy was started 30-60 minutes after completion of infusion.Patients of Group B received placebo in saline solution.A total of 66 patients were enrolled ( Group A:32 ; Group B:34 ),and four patients were unanalyzable,remaining 31 patients in each Group.Baseline factors were balanced.ResultsFollow-up rate was 97％.Group A vs.Group B:the overall response rate was 93.5％ vs.67.7％ ( x2 =6.61,P =0.01 ),2-year overall survival was 39.9％ vs.29.9％ ( x2 =0.62,P =0.433 ),2-year cancer specific survival was 43.1％ vs.26.8％ ( x2 =0.30,P =0.878),and 2-year progression-free survival was 30.1％ vs.27.9％ ( x2 =0.02,P =0.586).No severe side effects observed.All patients tolerated CMNa infusion well.Conclusions CMNa is tolerable and effective as a hypoxic radiosensitizer,and its combination with radiotherapy can improve short term effect.However,survival is not improved within our follow-up period.

The abnormality of serine/threonine kinase Aurora-A is seen in many types of cancers. Although in physiological context it has been shown to play a vital role in cellular mitosis, how this oncogene contributes to tumorigenesis remains unclear. Here we demonstrate that Aurora-A overexpression enhances both the expression level and transcriptional activity of c-Myc. The inhibition of c-Myc expression by RNA interference significantly impaired the oncogenic potential of Aurora-A, resulting in attenuated cellular proliferation and transformation rates as well as fewer centrosomal aberrations. Furthermore, downregulation of c-Myc effectively overcame Aurora-A-induced resistance to cisplatin in esophageal cancer cells. Taken together, our results suggest an important role for c-Myc in mediating the oncogenic activity of Aurora-A, which may in turn allow for future targeting of c-Myc as a potential therapeutic strategy for tumors with Aurora-A overexpression.
Cell Line, Transformed ; Cell Proliferation/drug effects ; Cell Transformation, Neoplastic/drug effects/genetics ; Centro ; Chromo ; Cisplatin/pharmacology ; Down-Regulation ; E ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Protein-Serine-Threonine Kinases/genetics/*metabolism ; Proto-Oncogene Proteins c-myc/genetics/*metabolism ; RNA, Small Interfering/genetics ; Transcriptional Activation ; Transgenes/genetics